Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005113 | 0.84 | FASN (0.58) | HPGDMAPK1GHSRACLYTSHR | |
| SCHEMBL22004127 | 0.83 | ACLY (0.51) | HPGDACLYALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL22004138 | 0.81 | ACLY (0.48) | HPGDACLYKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22004147 | 0.79 | ACLY (0.50) | HPGDACLYTSHRALDH1A1 | |
| SCHEMBL22004310 | 0.79 | ACLY (0.50) | HPGDACLYKMT2AMEN1ALDH1A1 | |
| SCHEMBL4465098 | 0.75 | CHRNA7 (0.51) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL22004341 | 0.73 | ACLY (0.46) | HPGDACLYKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3177575 | 0.73 | CHRNA7 (0.51) | HRH3 | |
| SCHEMBL21244768 | 0.72 | NR1I2 (0.48) | ACLYTSHRKMT2AALDH1A1LMNA | |
| SCHEMBL3174857 | 0.72 | KMT2A (0.54) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | HPGD 1212/4885MAPK1 4237/4885GHSR 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.